MedTrace Logo

A Safety and Tolerability Study of ILB® in Patients With Amyotrophic Lateral Sclerosis (ALS)

NCT03705390 · Status: TERMINATED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 11

Last updated 2025-06-26

Study results available
· View outcomes & findings →

Summary

This is a phase II study to determine the safety and tolerability of ILB®, a type of low molecular weight dextran sulfate, in patients with Motor Neurone Disease (MND)/ Amyotrophic Lateral Sclerosis (ALS)

Conditions

Interventions

DRUG

ILB®

Administration will be weekly subcutaneous injections at a dose of 2mg/kg once per week for up to a maximum of 48 weeks

Sponsors & Collaborators

  • TikoMed AB

    collaborator INDUSTRY

  • University Hospital Birmingham

    collaborator OTHER

  • Neuregenix Ltd

    collaborator UNKNOWN

  • University of Birmingham

    lead OTHER

Principal Investigators

  • Venkataramanan Srinivasan, MRCP, MRCP · University of Birmingham

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2019-03-29
Primary Completion
2021-07-28
Completion
2021-07-28

Countries

  • United Kingdom

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03705390 on ClinicalTrials.gov